JADPRO Live 2023

Blood Cancers Today covers updates in hematologic malignancies at JADPRO Live 2023, including myeloma news.

Advertisement

MajesTEC-1 Data Support Teclistamab Efficacy with Less Frequent Dosing

MajesTEC-1 Data Support Teclistamab Efficacy with Less Frequent Dosing

Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.

The Importance of Multiple Myeloma Educational Resources

The Importance of Multiple Myeloma Educational Resources

Dr. Coombs discussed the results from a survey of patients with myeloma and APPs who treat myeloma.

$Pooled Analysis Shows Elranatamab ‘Effective’ in Relapsed, Refractory Myeloma$

Pooled Analysis Shows Elranatamab ‘Effective’ in Relapsed, Refractory Myeloma

Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.

Patients, APPs Wish for Increased Educational Resources Surrounding MM

Patients, APPs Wish for Increased Educational Resources Surrounding MM

Of the 200 APPs surveyed, 72% reported being “generally knowledgeable” about MM before seeing their first patient.

Multiple Myeloma Research Foundation Empowers Patients with Right Track Framework

Multiple Myeloma Research Foundation Empowers Patients with Right Track Framework

Getting the right care team, treatment, and testing are three steps to empower patients with MM.